325 [18F]FDG-PET/CT to prevent futile surgery: a blinded, randomised controlled multicentre trial 4 Table 12. Subgroup analysis: therapeutic yield after one year of follow-up in AUS/FLUS, FN/SFN and HCN/SHCN nodules [18F]FDG-PET/CT-driven group diagnostic surgery group n % (95% CI) n % (95% CI) p non-Hürthle cell nodules, AUS/FLUS + FN/SFN (n=101) n=68 n=33 Beneficial management 43 / 68 63% (51%-75%) 5 / 33 15% (5%-32%) <0.001a Surgery for malignant/borderline nodule 20 / 68 29% (19%-42%) 5 / 33 15% (5%-32%) 0.12a Surveillance for benign nodule 23 / 68 34% (23%-46%) 0 / 33 0% (0%-11%) <0.001a Unbeneficial management 25 / 68 37% (25%-49%) 28 / 33 85% (68%-95%) <0.001a Surgery for benign nodule 25 / 68 37% (25%-49%) 28 / 33 85% (68%-95%) <0.001a Surveillance for malignant/borderline nodule 0 / 68 0 % (0%-5%) 0 / 33 0% (0%-11%) n.a. Avoided surgery in benign nodules 23 / 48 48% (33%-63%) 0 / 28 0% (0%-12%) <0.001a AUS/FLUS (n=60) n=40 n=20 Beneficial management 24 / 40 60% (43%-75%) 1 / 20 5% (0%-25%) <0.001a Surgery for malignant/borderline nodule 9 / 40 23% (11%-38%) 1 / 20 5% (0%-25%) 0.14b Surveillance for benign nodule 15 / 40 38% (23%-54%) 0 / 20 0% (0%-17%) 0.002a Unbeneficial management 16 / 40 40% (25%-57%) 19 / 20 95% (75%- 100%) <0.001a Surgery for benign nodule 16 / 40 40% (25%-57%) 19 / 20 95% (75%- 100%) <0.001a Surveillance for malignant/borderline nodule 0 / 40 0% (0%-9%) 0 / 20 0% (0%-17%) n.a. Avoided surgery in benign nodules 15 / 31 48% (30%-67%) 0 / 19 0% (0%-18%) <0.001a FN/SFN (n=41) n = 28 n = 13 Beneficial management 19 / 28 68% (48%-84%) 4 / 13 31% (9%-61%) 0.03a Surgery for malignant/borderline nodule 11 / 28 39% (22%-59%) 4 / 13 31% (9%-61%) 0.73b Surveillance for benign nodule 8 / 28 29% (13%-49%) 0 / 13 0% (0%-25%) 0.04b Unbeneficial management 9 / 28 32% (16%-52%) 9 / 13 69% (39%-91%) 0.03a Surgery for benign nodule 9 / 28 32% (16%-52%) 9 / 13 69% (39%-91%) 0.03a Surveillance for malignant/borderline nodule 0 / 28 0% (0%-12%) 0 / 13 0% (0%-25%) n.a. Avoided surgery in benign nodules 8 / 17 47% (23%-72%) 0 / 9 0% (0%-34%) 0.02b Hürthle cell nodules, HCN/SHCN (n=31) n=23 n=8 Beneficial management 10 / 23 43% (23%-66%) 2 / 8 25% (3%-65%) 0.43b Surgery for malignant/borderline nodule 8 / 23 35% (16%-57%) 1 / 8 13% (0%-53%) 0.38b Surveillance for benign nodule 2 / 23 9% (1%-28%) 1 / 8 13% (0%-53%) 1b Unbeneficial management 13 / 23 57% (34%-77%) 6 / 8 75% (35%-97%) 0.43b Surgery for benign nodule 13 / 23 57% (34%-77%) 6 / 8 75% (35%-97%) 0.43b Surveillance for malignant/borderline nodule 0 / 23 0% (0%-15%) 0 / 8 0% (0%-37%) n.a. Avoided surgery in benign nodules 2 / 15 13% (2%-40%) 1 / 7 14% (0%-58%) 1b AUS/FLUS=atypia of undetermined significance or follicular lesion of undetermined significance. FN/ SFN=cytology (suspicious for a) follicular neoplasm. HCN/SHCN=(suspicious for a) Hürthle cell neoplasm. N.a.=not applicable. a: Pearson’s chi-squared test. b: Fisher’s exact test.
RkJQdWJsaXNoZXIy MTk4NDMw